832695-04-2Relevant articles and documents
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
Curtin, Michael L.,Frey, Robin R.,Heyman, H. Robin,Soni, Niru B.,Marcotte, Patrick A.,Pease, Lori J.,Glaser, Keith B.,Magoc, Terrance J.,Tapang, Paul,Albert, Daniel H.,Osterling, Donald J.,Olson, Amanda M.,Bouska, Jennifer J.,Guan, Zhiwen,Preusser, Lee C.,Polakowski, James S.,Stewart, Kent D.,Tse, Chris,Davidsen, Steven K.,Michaelides, Michael R.
scheme or table, p. 3208 - 3212 (2012/06/18)
In an effort to identify multi-targeted kinase inhibitors with a novel spectrum of kinase activity, a screen of Abbott proprietary KDR inhibitors against a broad panel of kinases was conducted and revealed a series of thienopyridine ureas with promising activity against the Aurora kinases. Modification of the diphenyl urea and C7 moiety of these compounds provided potent inhibitors with good pharmacokinetic profiles that were efficacious in mouse tumor models after oral dosing. Compound 2 (ABT-348) of this series is currently undergoing Phase I clinical trials in solid and hematological cancer populations.
Improved synthesis of 3-substituted-4-amino-[3,2-c]-thienopyridines
Engstrom, Kenneth M.,Baize, Amanda L.,Franczyk, Thaddeus S.,Kallemeyn, Jeffrey M.,Mulhern, Mathew M.,Rickert, Robert C.,Wagaw, Seble
experimental part, p. 3849 - 3855 (2009/09/26)
(Chemical Equation Presented) Two syntheses of 3-substituted-4-amino-[3,2- c]thienopyridines have been developed to replace the standard literature route to these compounds, which uses unattractive conditions involving azide and high temperatures. The fir
Thienopyridine kinase inhibitors
-
Page 27, (2008/06/13)
Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.